États-Unis · Plateformes & données · Benzinga

Why Is Vir Biotechnology Stock Falling Friday?

Publié par Benzinga · États-Unis il y a 47 min

Résumé détaillé

Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10…

Lire l'article complet sur Benzinga Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.benzinga.com)

Why Is Vir Biotechnology Stock Falling Friday?

Résumé détaillé

À lire aussi

Moving iMage Technologies GAAP EPS of $0.02, revenue of $6.1M

ADI Global Distribution: 3 Key Takeaways for Long-Term Investors

Midterm elections provided the hyperscalers with the excuse they needed to cut back on spending, says Jefferies strategist

Thursday’s insider activity: Major buys and sells disclosed

U-wifi Names Charlie Vogt to its Board of Directors

Soon We’ll Need an Advanced AI Chip … Just to Understand the Nvidia Drama

Why Is Vir Biotechnology Stock Falling Friday?

Résumé détaillé

Partager

À lire aussi

Moving iMage Technologies GAAP EPS of $0.02, revenue of $6.1M

ADI Global Distribution: 3 Key Takeaways for Long-Term Investors

Midterm elections provided the hyperscalers with the excuse they needed to cut back on spending, says Jefferies strategist

Thursday’s insider activity: Major buys and sells disclosed

U-wifi Names Charlie Vogt to its Board of Directors

Soon We’ll Need an Advanced AI Chip … Just to Understand the Nvidia Drama